This presentation has a 2024 FDA label. The 2018 FDA document for the product used different renal wording. Check the product presentation and label date.
Before applying: Consult the exact cited section and other applicable sources before use.
Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist
Choose a source to read (2)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
Official source
Bydureon - labeled renal guidance
Renal action and limits
Exenatide (Bydureon), extended-release powder and diluent for SC injection Indexed GFR/eGFR, mL/min/1.73 m2
This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.
Action or finding
Use is not recommended below eGFR 45 or in end-stage renal disease. Monitor patients with mild impairment for effects that can cause hypovolemia.
Limits and monitoring
Verify the presentation and source date. In renal transplant recipients, monitor closely for adverse effects that deplete volume.
Before use
This presentation has a 2024 FDA label. The 2018 FDA document for the product used different renal wording. Check the product presentation and label date.
Exenatide (Bydureon), extended-release powder and diluent for SC injection
Renal measure
Indexed GFR/eGFR, mL/min/1.73 m2
Source revision
Prescribing information revised 11/2024
Retrieved
2026-11-07 (not the revision date)
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Renal guidance: 8.6
Use is not recommended below eGFR 45 or in end-stage renal disease. Monitor patients with mild impairment for effects that can cause hypovolemia. Verify the presentation and source date. In renal transplant recipients, monitor closely for adverse effects that deplete volume.
Source revision: Prescribing information revised 11/2024 | Retrieved: 2026-11-07. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
Source scope / renal recommendation differences
Bydureon - product and source limitations
This presentation has a 2024 FDA label. The 2018 FDA document for the product used different renal wording. Check the product presentation and label date.
How to use this: This presentation has a 2024 FDA label. The 2018 FDA document for the product used different renal wording. Check the product presentation and label date.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Official source
Bydureon - labeled renal guidance
Exenatide (Bydureon), extended-release powder and diluent for SC injection
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Use is not recommended below eGFR 45 or in end-stage renal disease. Monitor patients with mild impairment for effects that can cause hypovolemia. Verify the presentation and source date. In renal transplant recipients, monitor closely for adverse effects that deplete volume.
GlobalRPh RX List / product-label mirror · Exenatide (Bydureon), extended-release powder and diluent for SC injection
Renal method: Use the renal measure explicitly present in the RX passage. Source date: Mirror revision not established in the reviewed passage. Retrieved: 2026-11-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.
